In last trading session, AC Immune SA (NASDAQ:ACIU) saw 0.18 million shares changing hands with its beta currently measuring 0.53. Company’s recent per share price level of $2.57 trading at -$0.13 or -4.81% at ring of the bell on the day assigns it a market valuation of $215.42M. That closing price of ACIU’s stock is at a discount of -110.51% from its 52-week high price of $5.41 and is indicating a premium of 19.84% from its 52-week low price of $2.06. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 65200.0 shares which gives us an average trading volume of 68.52K if we extend that period to 3-months.
For AC Immune SA (ACIU), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.30. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.25 in the current quarter.
AC Immune SA (NASDAQ:ACIU) trade information
Upright in the red during last session for losing -4.81%, in the last five days ACIU remained trading in the green while hitting it’s week-highest on Thursday, 11/17/22 when the stock touched $2.57 price level, adding 17.1% to its value on the day. AC Immune SA’s shares saw a change of -48.08% in year-to-date performance and have moved 0.39% in past 5-day. AC Immune SA (NASDAQ:ACIU) showed a performance of -13.61% in past 30-days. Number of shares sold short was 0.48 million shares which calculate 5.8 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $12.46 to the stock, which implies a rise of 79.37% to its current value. Analysts have been projecting $8.99 as a low price target for the stock while placing it at a high target of $15.94. It follows that stock’s current price would drop -520.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of -249.81% for stock’s current value.
AC Immune SA (ACIU) estimates and forecasts
Statistics highlight that AC Immune SA is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -18.41% of value to its shares in past 6 months, showing an annual growth rate of 13.21% while that of industry is 4.60. Apart from that, the company came raising its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -4.20% in the current quarter and calculating 6.90% increase in the next quarter.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $230k for the same. And 3 analysts are in estimates of company making revenue of $1.39 million in the next quarter that will end on Dec 2022.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -47.00% during past 5 years.
AC Immune SA is more likely to be releasing its next quarterly report on October 28 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
AC Immune SA (NASDAQ:ACIU)’s Major holders
Insiders are in possession of 47.74% of company’s total shares while institution are holding 18.04 percent of that, with stock having share float percentage of 34.51%. Investors also watch the number of corporate investors in a company very closely, which is 18.04% institutions for AC Immune SA that are currently holding shares of the company. BVF Inc. is the top institutional holder at ACIU for having 7.43 million shares of worth $26.82 million. And as of Jun 29, 2022, it was holding 8.89% of the company’s outstanding shares.
The second largest institutional holder is Morgan Stanley, which was holding about 1.97 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 2.36% of outstanding shares, having a total worth of $7.11 million.
On the other hand, iShares NASDAQ Biotechnology ETF and SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF are the top two Mutual Funds which own company’s shares. As of Sep 29, 2022, the former fund manager was holding 0.33 million shares of worth $1.03 million or 0.39% of the total outstanding shares. The later fund manager was in possession of 56869.0 shares on Aug 30, 2022, making its stake of worth around $0.17 million in the company or a holder of 0.07% of company’s stock.